SaiTuo Bio disclosed its 2026 semi-annual report on August 29. In the first half of the year, it achieved total operating revenue of 613 million yuan, up 20.67 percent year on year, and net profit attributable to the parent company of 30.23 million yuan, turning from a loss to a profit compared with the same period last year. Non-recurring net profit was 29.28 million yuan, also turning profitable. Net cash flow from operating activities was 121 million yuan, up 92.61 percent year on year. Basic earnings per share were 0.16 yuan, and the weighted average return on equity was 1.70 percent, up 4.61 percentage points year on year. The company's main business is manufacturing and selling steroid drug raw materials and intermediates using genetic engineering technology and microbial transformation technology.
Shandong Sito Bio-technology Co LtdTurned profitable with net profit of 30.23 million yuan, revenue up 20.67%.
